微信公众号

官网二维码
中国癌症防治杂志

中国癌症防治杂志 ›› 2016, Vol. 8 ›› Issue (2): 122-125.doi: 10.3969/j.issn.1674-5671.2016.02.12

• 临床经验 • 上一篇    下一篇

伊立替康或依托泊苷联合顺铂一线治疗广泛期小细胞肺癌的疗效比较

  

  1. 河南省信阳市中心医院肿瘤内科二病区
  • 出版日期:2016-04-25 发布日期:2016-05-13
  • 通讯作者: 柏峰 xybaifeng@sina.com

Comparison of safety and efficacy of irinotecan or etoposide combined with cisplatin as first-line treatment for extensive stage small cell lung cancer

  • Online:2016-04-25 Published:2016-05-13

PDF (PC)

479

赞

被引次数

2

摘要：

目的 比较伊立替康联合顺铂（irinotecan plus cisplatin，IP）与依托泊苷联合顺铂（etoposide plus cisplatin，EP）两种方案一线治疗广泛期小细胞肺癌（extensive-disease small cell lung cancer，ED-SCLC）的临床疗效和毒副反应。方法 初治ED-SCLC患者50例，予IP方案治疗25例，顺铂（DDP） 30 mg/m2静脉滴注，d1~d3；伊立替康（CPT-11）150 mg/m2静脉滴注，d1；予EP方案治疗25例，DDP 30 mg/m2静脉滴注，d1~d3；依托泊苷（Vp-16）60 mg/m2静脉滴注，d1~d5，两种方案均以21 d为1个周期，连续化疗4个周期，每2个周期评价疗效及毒副反应。结果 IP方案和EP方案有效率分别为72.0％、64.0％，差异无统计学意义（P=0.544）；两种方案血液学毒性发生率的差异无统计学意义（P>0.05），但IP方案腹泻发生率明显高于EP方案（P=0.002）。结论 伊立替康联合顺铂或依托泊苷联合顺铂一线治疗广泛期小细胞肺癌的疗效相似，患者均可耐受。

关键词: 肺肿瘤, 伊立替康, 依托泊苷, 顺铂, 化疗, 疗效

Abstract:

Objective To compare the clinical efficacy and adverse effects of the combination of irinotecan and cisplatin （IP） with the combination of etoposide and cisplatin（EP） as first-line therapy regimen for extensive-disease small cell lung cancer （ED-SCLC）. Methods ED-SCLC patients were assigned to receive IP（n =25；150 mg/m2 irinotecan on day l and 30 mg/m2 cisplatin on days 1-3） or EP（n=25； 60 mg/m2 etoposide on days 1-5 and 30 mg/m2 cisplatin on days 1-3）. Treatments were repeated every 3 weeks for a total of 4 cycles. Clinical efficacy and adverse effects were assessed every 2 cycles. Results Response rates（RR） were 72% with IP and 64% with EP （P=0.544）. The two regimens were associated with a similar rate of hematologic toxicity（P>0.05），while the IP regimen was associated with a significantly higher rate of diarrhea（P=0.002）. Conclusion Clinical efficacy may be similar for IP and EP as first-line therapy for ED-SCLC，and adverse effects appear to be tolerable in both cases.

Key words: Lung neoplasm, Irinotecan, Etoposide, Cisplatin, Chemotherapy, Efficacy